James Horton, MD
Endocrinology, Diabetes & Metabolism · Greenville, SCNPI 1750321998
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,310 of the $73,147 with a category attached, or 85.2%. Novo Nordisk accounts for 63.6% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2019 at $33,052 and has fallen 99.6% since, to $125 in 2024.
Across 574 payments — averaging $127.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$47K
- Sanofi-aventis U.S. LLC$19K
- AstraZeneca$760
- Lilly USA, LLC$684
- Boehringer Ingelheim$495
- AbbVie$493
- plus $5K from 38 others
What the payments were for
- Speaking & faculty fees$62,31085%
- Travel & lodging$1,7422%
- Food & beverage$9,06712%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$15,446
- RYBELSUS$13,718
- SOLIQUA 100/33$10,762
- Ozempic$8,863
- TOUJEO$7,802
- Xultophy 100/3.6$5,265
- Omnipod$125
How this compares
$73,147 in reported general payments places this provider in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 33 | $82,746 |
| OzempicSemaglutide | 58 | $71,049 |
| JardianceEmpagliflozin | 32 | $50,578 |
| FarxigaDapagliflozin Propanediol | 43 | $41,556 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $36,085 |
| TrulicityDulaglutide | 16 | $29,258 |
| Desmopressin Acetate | 16 | $27,870 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $27,269 |
| JanuviaSitagliptin Phosphate | 21 | $26,867 |
| MounjaroTirzepatide | 22 | $25,363 |
| SynthroidLevothyroxine Sodium | 195 | $17,615 |
| Novolog FlexpenInsulin Aspart | 51 | $15,713 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $10,548 |
| Testosterone | 25 | $9,528 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $8,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $46,505 | $71,04958 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $684 | $54,62238 claims |
| Boehringer IngelheimJardiance | $495 | $50,57832 claims |
| AstraZenecaFarxiga | $760 | $41,55643 claims |
| MerckJanuvia | $85 | $26,86721 claims |
| AbbVieSynthroid | $493 | $17,615195 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $268 | $7,887904 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Greenville
- Cory WhiteGreenville$413K
- Mojgan RahmaniyanGreenville$6K
- Sandra WeberGreenville$5K
- John BruchGreenville$4K
- Gregory SchleisGreenville$2K
- Gauri DhirMyrtle Beach$417K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.